Clinuvel Pharmaceuticals (ASX:CUV) said four patients with darker skin types enrolled in its study of drug candidate Scenesse in the treatment of vitiligo reported satisfaction with the treatment, which was also well tolerated, according to a Thursday filing with the Australian bourse.

The patients had received seven implants of the drug candidate and up to 40 adjunct narrowband ultraviolet B phototherapy sessions, the filing said.

Shares of the company rose 2% in recent Thursday trade.